Meetings to be held in Boston on May 15 and in Chicago on May 16 hosted by Oppenheimer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
- Nurix Therapeutics initiated with an Overweight at Stephens
- Nurix Therapeutics management to meet with Oppenheimer
- Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
- Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares